| Literature DB >> 19519903 |
Jörg Handschel1, Melani Simonowska, Christian Naujoks, Rita A Depprich, Michelle A Ommerborn, Ulrich Meyer, Norbert R Kübler.
Abstract
UNLABELLED: Several grafting materials have been used in sinus augmentation procedures including autogenous bone, demineralized freeze-dried bone (DFDBA), hydroxyapatite, beta-tricalcium phosphate (beta-TCP), anorganic deproteinized bovine bone and combination of these and others. Up to now a subject of controversy in maxillofacial surgery and dentistry is, what is the most appropriate graft material for sinus floor augmentation.Entities:
Mesh:
Substances:
Year: 2009 PMID: 19519903 PMCID: PMC2700082 DOI: 10.1186/1746-160X-5-12
Source DB: PubMed Journal: Head Face Med ISSN: 1746-160X Impact factor: 2.151
Selection of evaluable articles by in- and exclusion criteria
| After initial literature search | 120 | |
| English or german | 4 | 116 |
| Only human (no animal studies) | 4 | 112 |
| No interviews/editorials | 6 | 106 |
| Only external sinus floor elevation | 25 | 81 |
| Only autogenous bone, demineralized freeze-dried bone (DFDBA), hydroxyapatite, β-tricalcium phosphate (β-TCP), anorganic deproteinized bovine bone [ | 16 | 65 |
| TBV evaluable | 35 | 30 |
Distribution of articles and material observations
| Studies | 30 | 3 | 1 | 26 |
| Examined grafting materials (in these studies) | 53 | 4 | 3 | 46 |
Selection of evaluable material observations by three exclusion criteria
| Algipore® | 1 | 0 | 0 | 0 | 1 |
| Bio Oss® | 18 | 4 | 3 | 5 | 13* |
| Bio Oss® + autogen | 8 | 0 | 0 | 0 | 8* |
| DFDBA | 1 | 1 | 0 | 1 | 0 |
| HA | 3 | 1 | 0 | 1 | 2 |
| Autogen | 13 | 3 | 5 | 4 | 9* |
| Autogen + DFDBA 50:50 | 1 | 0 | 0 | 0 | 1 |
| Autogen + HA 50:50 | 1 | 0 | 0 | 0 | 1 |
| β-TCP | 7 | 1 | 1 | 1 | 6* |
| Σ | 53 | 17 | 5 | 18 | 41 (36) |
Note the numbers with * show the grafting materials with at least three reported observations (criteria III).
List of reviewed publications.
| Artzi Z. et al. | 2001 | BioOss | 12.00 | 10 | 32.20 | 8.150 |
| Artzi Z. et al. | 2001 | HA | 12.00 | 10 | 42.10 | 10.010 |
| Artzi Z. et al. | 2002 | BioOss | 12.00 | 10 | 43.61 | 8.601 |
| Artzi Z. et al. | 2003 | HA | 12.00 | 10 | 32.95 | 7.991 |
| Artzi Z. et al. | 2005 | BioOss | 12.00 | 12 | 45.60 | 10.900 |
| Artzi Z. et al. | 2005 | β-TCP | 12.00 | 12 | 32.00 | 8.400 |
| Boeck-Neto RJ. et al. | 2002 | autogen+DFDBA | 10.00 | 5 | 50.46 | 16.290 |
| Boeck-Neto RJ. et al. | 2002 | autogen+HA | 10.00 | 5 | 46.79 | 8.560 |
| Degidi M. et al. | 2004 | BioOss+autogen | 6.00 | 12 | 38.80 | 3.200 |
| Froum SJ. et al. | 2002 | BioOss | 7.25 | 2 | 16.00 | 4.243 |
| Froum SJ. et al. | 2002 | BioOss | 11.00 | 1 | 32.00 | . |
| Fugazotto PA. et al. | 2003 | BioOss | 6.88 | 26 | 52.85 | 19.605 |
| Fugazotto PA. et al. | 2003 | BioOss | 12.50 | 5 | 68.80 | 7.400 |
| Hallman M. et al. | 2001 | BioOss+autogen | 7.00 | 16 | 24.70 | 16.901 |
| Hallman M. et al. | 2001 | BioOss+autogen | 30.00 | 12 | 50.70 | 22.800 |
| Hallman M. et al. | 2002 | Autogen | 12.50 | 11 | 37.70 | 31.300 |
| Hallman M. et al. | 2002 | BioOss | 14.75 | 10 | 39.90 | 8.000 |
| Hallman M. et al. | 2002 | BioOss+autogen | 12.50 | 11 | 41.70 | 26.600 |
| John HD. et al. | 2004 | Autogen | 5.50 | 4 | 53.50 | 2.520 |
| John HD. et al. | 2004 | BioOss | 5.50 | 21 | 29.52 | 7.430 |
| John HD. et al. | 2004 | BioOss+autogen | 5.50 | 13 | 32.23 | 6.860 |
| Karabuda C. et al. | 2001 | BioOss | 6.00 | 5 | 50.00 | . |
| Karabuda C. et al. | 2001 | DFDBA | 6.00 | 1 | 72.50 | . |
| Karabuda C. et al. | 2001 | HA | 6.00 | 3 | 27.50 | 8.660 |
| Ozyuvaci H. et al. | 2003 | BioOss | 7.00 | 44 | 47.50 | 0.945 |
| Ozyuvaci H. et al. | 2003 | β-TCP | 7.00 | 44 | 52.50 | 0.945 |
| Proussaefs P. et al. | 2003 | BioOss | 11.00 | 5 | 34.40 | 10.810 |
| Scarano A. et al. | 2004 | BioOss | 53.00 | 1 | 38.00 | . |
| Schopper C. et al. | 2003 | Algipore | 7.00 | 26 | 23.00 | 8.300 |
| Szabo G. et al. | 2001 | Autogen | 6.00 | 4 | 37.05 | 8.842 |
| Szabo G. et al. | 2001 | β-TCP | 6.00 | 4 | 29.37 | 10.568 |
| Szabo G. et al. | 2005 | Autogen | 6.00 | 20 | 38.34 | 7.400 |
| Szabo G. et al. | 2005 | β-TCP | 6.00 | 20 | 36.47 | 6.900 |
| Tadjoedin ES et al. | 2000 | Autogen | 5.00 | 9 | 42.28 | 3.251 |
| Tadjoedin ES et al. | 2000 | Autogen | 16.00 | 1 | 45.07 | . |
| Tadjoedin ES et al. | 2002 | Autogen | 5.00 | 2 | 40.05 | 1.061 |
| Tadjoedin ES et al. | 2002 | Autogen | 15.00 | 1 | 41.70 | . |
| Tadjoedin ES et al. | 2003 | Autogen | 5.00 | 1 | 37.30 | . |
| Tadjoedin ES et al. | 2003 | BioOss | 8.00 | 1 | 22.90 | . |
| Tadjoedin ES et al. | 2003 | BioOss+autogen | 6.33 | 3 | 29.57 | 4.508 |
| Trisi P. et al. | 2003 | BioOss+autogen | 15.33 | 9 | 44.38 | 8.575 |
| Turunen T. et al. | 2004 | Autogen | 6.75 | 14 | 25.10 | 7.200 |
| Turunen T. et al. | 2004 | Autogen | 13.75 | 4 | 25.10 | 6.300 |
| Valentini P. et al. | 2000 | BioOss | 6.00 | 3 | 21.08 | 7.250 |
| Valentini P. et al. | 2000 | BioOss | 12.00 | 3 | 27.55 | 4.880 |
| Wallace SS. et al. | 2005 | BioOss | 8.00 | 153 | 15.53 | 8.023 |
| Yildrim M. et al. | 2000 | BioOss | 7.00 | 11 | 14.70 | 5.000 |
| Yildrim M. et al. | 2001 | BioOss+autogen | 7.75 | 12 | 18.90 | 6.400 |
| Zerbo IR. et al. | 2001 | β-TCP | 8.00 | 1 | 20.00 | . |
| Zerbo IR. et al. | 2004 | Autogen | 6.00 | 5 | 41.00 | 10.000 |
| Zerbo IR. et al. | 2004 | β-TCP | 6.00 | 9 | 17.00 | 5.000 |
| Zijderveld SA. et al. | 2005 | Autogen | 6.00 | 5 | 41.00 | 10.000 |
| Zijderveld SA. et al. | 2005 | β-TCP | 6.00 | 9 | 17.00 | 5.000 |
n = number of patients
Figure 1Correlation of TBV and time after grafting. The size of the bubbles reflect the relative weight of the value. Black: Bio Oss®, red: Bio Oss® with autogenous bone, blue: autogeneous bone, green: β-TCP.
Figure 2TBV after 4 until 9 months. Shown are the values and the SD of the weighted mean. The dashed lines mark the statistical significant differences.
Figure 3TBV after more than 9 months. Shown are the values and the SD of the weighted mean.